Japan’s pharmaceutical industry relies on overseas sources for nearly 90% of its active ingredients. A disruption in supply could ripple far beyond Japan, affecting hospitals and pharmacies worldwide. Medicines are resources directly tied to human lives, and border risks carry the potential to trigger not only economic disruption but also widespread social anxiety.
In this article, I outline how the United States, China, and Japan are responding to border risks, and explore how these strategies may shape global health security. I also discuss the potential emergence of new professional roles and insurance mechanisms to strengthen resilience in pharmaceutical supply chains.
👉 The full article is available exclusively to Medium members.
Read more here:
Japan’s Pharmaceutical Industry and Border Risks — Global Fears and the Design of Resilience
